HIGHLIGHTS
- who: Radioimmunotherapy . Radioimmunoconjugate . et al. from the Institute of Clinical Medicine, University of have published the Article: Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate Lu-NNV003, in the Journal: (JOURNAL)
- what: The authors show that 177LuNNV003 increased survival of mice with xenografts of human CLL, MCL and DLBCL.
- how: To compare the anti-tumour effect of 177Lu-NNV003 and NNV003 therapies were tested in a s.c. model where 10 × 106 REC-1 cells were injected s.c. in each flank of female nude
SUMMARY
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.